Key result
Elevated Lp(a) linked to ~2.6-fold higher risk of recurrent vascular events after ischemic stroke.
Why the study?
Evidence on the association between elevated lipoprotein(a) levels and residual vascular risk in stroke survivors is lacking.
Does elevated Lipoprotein(a) >30 mg/dL increase the risk of recurrent vascular events in patients with first-ever ischemic stroke?
Cohort (n=250)
No
Does elevated Lipoprotein(a) >30 mg/dL increase the risk of recurrent vascular events in patients with first-ever ischemic stroke?
Answers are grounded in this paper and cite their sources.
Elevated Lipoprotein(a) >30 mg/dL is associated with a more than two-fold increased risk of recurrent vascular events in survivors of a first-ever ischemic stroke.
Background and Purpose— The association of elevated lipoprotein(a) (Lp(a)) levels and the incidence of cardiovascular disease, especially coronary heart disease and ischemic stroke, is well established. However, evidence on the association between Lp(a) levels and residual vascular risk in stroke survivors is lacking. We aimed to elucidate the risk for recurrent cardiovascular and cerebrovascular events in the patients with first-ever ischemic stroke with elevated Lp(a). Methods— All patients with acute ischemic stroke who participated in the prospective Berlin C&S study (Cream & Sugar) between January 2009 and August 2014 with available 12-month follow-up data and stored blood samples were eligible for inclusion. Lp(a) levels were determined in serum samples using an isoform-insensitive nephelometry assay. We assessed the risk for the composite vascular end point of ischemic stroke, transient ischemic attack, myocardial infarction, nonelective coronary revascularization, and cardiovascular death with elevated Lp(a) defined as >30 mg/dL using Cox regression analyses. Results— Of 465 C&S study participants, 250 patients were included into this substudy with a median National Institutes of Health Stroke Scale score of 2 (1–4). Twenty-six patients (10%) experienced a recurrent vascular event during follow-up. Among patients with normal Lp(a) levels, 11 of 157 subjects (7%) experienced an event at a median time of 161 days (interquartile range, 19–196 days), whereas in patients with elevated Lp(a) levels, 15 of 93 subjects (16%) experienced an event at a median time of 48 days (interquartile range, 9–194 days; P =0.026). The risk for a recurrent event was significantly higher in patients with elevated Lp(a) levels after adjustment for potential confounders (hazard ratio, 2.60; 95% confidence interval, 1.19–5.67; P =0.016). Conclusions— Elevated Lp(a) levels are associated with a higher risk for combined vascular event recurrence in patients with acute, first-ever ischemic stroke. This finding should be validated in larger, multicenter trials. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT01378468.
No takes yet. Share an insight, caveat, or question.
Lange et al. (2016) conducted a cohort in Acute ischemic stroke (n=250). Elevated Lipoprotein(a) (>30 mg/dL) vs. Normal Lipoprotein(a) levels (≤30 mg/dL) was evaluated on Composite vascular end point of ischemic stroke, transient ischemic attack, myocardial infarction, nonelective coronary revascularization, and cardiovascular death (HR 2.60, 95% CI 1.19-5.67, p=0.016). Elevated Lipoprotein(a) levels were associated with a higher risk for recurrent vascular events after first-ever ischemic stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: